Latest Teleradiology News

Integral Diagnostics (ASX: IDX) delivered a robust FY26 with 26% revenue growth to $788.6 million, a 677% surge in profit after tax to $22 million, and a 50% hike in its final dividend to 6 cents per share.

Mach7 Technologies delivered a positive operating cash flow in Q4 FY26, boosted its ARR run rate by 7.6% in constant currency, and secured multi-year subscription deals while expanding its partner ecosystem.

Infratil posted an 11% rise in operational EBITDAF to NZ$989 million in FY26, fuelled by a record 555MW CDC data centre contract and a 170% EBITDAF jump at Longroad Energy. The company refined its portfolio with over NZ$600 million in divestments and secured a BBB+ credit rating, underpinning a strong FY27 outlook.

Mach7 Technologies has secured a five-year, A$1.7 million subscription contract with US teleradiology provider AMRADNET, slashing deployment time from 12 months to just 45 days.

Integral Diagnostics Limited has reported a robust half-year performance, with revenues soaring 55.6% and EBITDA nearly doubling, driven by strong patient volume growth and successful integration of Capitol Health. The company also declared a fully franked interim dividend of 3.3 cents per share.

Mach7 Technologies has been notified that the Veterans Health Administration will cease its NextGen PACS program, leading to a partial stop work order and cancellation of Phase 2 of the contract. Despite this, Mach7 remains focused on its broader commercial strategy.

Integral Diagnostics reports a robust FY25 with revenue climbing 33.7% to $628 million, driven by successful Capitol Health merger integration and strong growth in teleradiology. CEO Dr Ian Kadish announces retirement after eight transformative years.

Mach7 Technologies reports a pivotal first quarter for FY26, marked by the initial go-live of a major U.S. Veterans Health Administration contract, leadership changes, and a strategic business reset.

Mach7 Technologies has initiated Phase 1 of the Veterans Health Administration’s National Teleradiology Program, deploying its core imaging software across 125 sites. This milestone sets the stage for a potential $11.7 million contract and broader expansion within the VHA network.

Integral Diagnostics (IDX) reported a robust FY25 with 33.7% revenue growth and operating EBITDA margin expansion, driven by the Capitol merger and organic growth. The company exceeded synergy expectations and outlined a confident outlook amid favourable industry tailwinds.

Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.

Integral Diagnostics Limited (ASX – IDX) reported a robust FY25 performance, boosted by its transformative merger with Capitol Health Limited. The company posted strong revenue and profit growth, declared a 4.0 cent final dividend, and outlined strategic priorities including AI adoption and teleradiology expansion.